Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The fate of 23andMe (MEHCQ) and the treasure trove of data it has on its users is set to be fought over in court. Yahoo ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

TTAM Research Institute, a nonprofit public benefit corporation based in California and led by 23andMe co-founder and former ...

AndMe had “inadequate” security systems and was “slow to respond” to warning signs customers’ sensitive data was at risk before the "profoundly damaging" hack, officials say.

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The once-popular genetic testing company is being acquired by a nonprofit led by a 23andMe co-founder, as questions persist about how to remove personal data from it.